Literature DB >> 26160001

Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy.

Jian Guo1, Anton Mihic1, Jun Wu1, Yuemei Zhang1, Kaustabh Singh1, Sanjiv Dhingra1, Richard D Weisel1, Ren-Ke Li2.   

Abstract

AIMS: A mismatch between adequate angiogenesis and overgrowth of myocytes may be a critical mechanism controlling the transition from adaptive hypertrophy to heart failure. Canopy 2 (CNPY2) was recently identified as a secreted, HIF-1α-regulated angiogenic growth factor. As angiogenic factors play important roles in the development of myocardial hypertrophy, we investigated the role of CNPY2 in molecular and functional changes during development of chronic heart failure using cardiac-specific transgenic (TG) mice that overexpress human CNPY2. METHODS AND
RESULTS: We generated TG mice that constitutively express CNPY2 in the myocardium. Cardiomyopathy was induced in TG and wild-type (WT) mice by transverse aortic constriction (TAC). WT mice developed significant ventricular hypertrophy at 4 weeks and severe dilatation and heart failure at 12 weeks after TAC. However, TG mice preserved much better cardiac structure and function, with less severe ventricular dilatation and markedly reduced cardiac apoptosis and fibrosis following TAC. Excess CNPY2 in TG mice prevented significant loss of vasculature up to 12 weeks after TAC injury, resulting in a better local myocardial environment that facilitated myocyte survival and prevented excessive matrix remodelling compared with WT mice. TG mice had less accumulation of endogenous tumor suppressor p53 after TAC, indicating intrinsic activation of the p53-mediated repression of HIF-1α, and Cnpy2 was diminished in TG mice compared with WT controls.
CONCLUSION: Our study showed a correlation between downregulation of endogenous mouse Cnpy2 and p53-mediated HIF-1α inhibition during late-stage hypertrophic development. Additional CNPY2 attenuated the transition from compensatory hypertrophic response to maladaptive ventricular dilatation and heart failure. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Angiogenesis; CNPY2; HIF-1α; Heart failure; Hypertrophy; p53

Mesh:

Substances:

Year:  2015        PMID: 26160001      PMCID: PMC4589657          DOI: 10.1093/eurheartj/ehv294

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  18 in total

Review 1.  Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?

Authors:  Pitchai Balakumar; Gowraganahalli Jagadeesh
Journal:  Pharmacol Res       Date:  2010-07-17       Impact factor: 7.658

2.  Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap).

Authors:  Hai Thi Do; Timofey V Tselykh; Johanna Mäkelä; Tho Huu Ho; Vesa M Olkkonen; Beat C Bornhauser; Laura Korhonen; Noam Zelcer; Dan Lindholm
Journal:  J Biol Chem       Date:  2012-02-29       Impact factor: 5.157

3.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

Authors:  R Ravi; B Mookerjee; Z M Bhujwalla; C H Sutter; D Artemov; Q Zeng; L E Dillehay; A Madan; G L Semenza; A Bedi
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

Review 4.  Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies.

Authors:  Bianca C Bernardo; Kate L Weeks; Lynette Pretorius; Julie R McMullen
Journal:  Pharmacol Ther       Date:  2010-05-12       Impact factor: 12.310

5.  Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF).

Authors:  Richard P Visconti; Charlene D Richardson; Thomas N Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-04       Impact factor: 11.205

6.  p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload.

Authors:  Masanori Sano; Tohru Minamino; Haruhiro Toko; Hideyuki Miyauchi; Masayuki Orimo; Yingjie Qin; Hiroshi Akazawa; Kaoru Tateno; Yosuke Kayama; Mutsuo Harada; Ippei Shimizu; Takayuki Asahara; Hirofumi Hamada; Shuhei Tomita; Jeffrey D Molkentin; Yunzeng Zou; Issei Komuro
Journal:  Nature       Date:  2007-03-04       Impact factor: 49.962

7.  Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload.

Authors:  Ping Hu; Dongfang Zhang; LeAnne Swenson; Gopa Chakrabarti; E Dale Abel; Sheldon E Litwin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-08       Impact factor: 4.733

8.  MSAP is a novel MIR-interacting protein that enhances neurite outgrowth and increases myosin regulatory light chain.

Authors:  Beat C Bornhauser; Per-Anders Olsson; Dan Lindholm
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

Review 9.  Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure.

Authors:  Toru Oka; Issei Komuro
Journal:  Circ J       Date:  2008-09-05       Impact factor: 2.993

10.  Expression of CNPY2 in mouse tissues: quantification and localization.

Authors:  Kota Hatta; Jian Guo; Ana Ludke; Sanjiv Dhingra; Kaustabh Singh; Ming-Li Huang; Richard D Weisel; Ren-Ke Li
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

View more
  13 in total

1.  Entresto therapy effectively protects heart and lung against transverse aortic constriction induced cardiopulmonary syndrome injury in rat.

Authors:  Hung-I Lu; Meng-Shen Tong; Kuan-Hung Chen; Fan-Yen Lee; John Y Chiang; Sheng-Ying Chung; Pei-Hsun Sung; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  Steroid receptor coactivator-2 (SRC-2) coordinates cardiomyocyte paracrine signaling to promote pressure overload-induced angiogenesis.

Authors:  Ji Ho Suh; Li Lai; Deokhwa Nam; Jong Kim; Juyeon Jo; George E Taffet; Eunah Kim; Jason T Kaelber; Hyun-Kyoung Lee; Mark L Entman; John P Cooke; Erin L Reineke
Journal:  J Biol Chem       Date:  2017-11-10       Impact factor: 5.157

3.  Fine-tuning PERK signaling to control cell fate under stress.

Authors:  Hery Urra; Claudio Hetz
Journal:  Nat Struct Mol Biol       Date:  2017-10-05       Impact factor: 15.369

4.  MiR-221-3p targets Hif-1α to inhibit angiogenesis in heart failure.

Authors:  Yuying Li; Chenghui Yan; Jiahui Fan; Zhiwei Hou; Yaling Han
Journal:  Lab Invest       Date:  2020-09-01       Impact factor: 5.662

Review 5.  Feedback regulation of RTK signaling in development.

Authors:  Cynthia L Neben; Megan Lo; Natalia Jura; Ophir D Klein
Journal:  Dev Biol       Date:  2017-10-26       Impact factor: 3.582

6.  Expression of a novel CNPY2 isoform in colorectal cancer and its association with oncologic prognosis.

Authors:  Jianhong Peng; Qingjian Ou; Jian Guo; Zhizhong Pan; Rongxin Zhang; Xiaojun Wu; Yujie Zhao; Yuxiang Deng; Caixia Li; Fulong Wang; Liren Li; Gong Chen; Zhenhai Lu; Peirong Ding; Desen Wan; Yujing Fang
Journal:  Aging (Albany NY)       Date:  2017-11-13       Impact factor: 5.682

7.  A novel liver metastasis-correlated protein of pancreatic neuroendocrine neoplasm (PanNEN) discovered by proteomic analysis.

Authors:  Mitsuhiro Shimura; Masamichi Mizuma; Tatsuyuki Takadate; Yasutake Katoh; Takashi Suzuki; Masahiro Iseki; Tatsuo Hata; Shuichi Aoki; Yukie Suzuki; Naoaki Sakata; Hideo Ohtsuka; Hiroki Hayashi; Takanori Morikawa; Kei Nakagawa; Fuyuhiko Motoi; Takeshi Naitoh; Kazuhiko Igarashi; Hironobu Sasano; Michiaki Unno
Journal:  Oncotarget       Date:  2018-05-11

8.  Protective effect of Barbaloin in a rat model of myocardial ischemia reperfusion injury through the regulation of the CNPY2‑PERK pathway.

Authors:  Yue Cui; Yongqiang Wang; Gang Liu
Journal:  Int J Mol Med       Date:  2019-03-05       Impact factor: 4.101

9.  Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury.

Authors:  Chong Liu; Yong Liu; Jing He; Rong Mu; Yanbo Di; Na Shen; Xuan Liu; Xiao Gao; Jinhui Wang; Tie Chen; Tao Fang; Huanming Li; Fengshi Tian
Journal:  Front Pharmacol       Date:  2019-07-24       Impact factor: 5.810

10.  CNPY2 is a key initiator of the PERK-CHOP pathway of the unfolded protein response.

Authors:  Feng Hong; Bei Liu; Bill X Wu; Jordan Morreall; Brady Roth; Christopher Davies; Shaoli Sun; J Alan Diehl; Zihai Li
Journal:  Nat Struct Mol Biol       Date:  2017-09-04       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.